Search / Trial NCT00001120

A Study of Patients With AIDS Syndrome

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of December 27, 2024

Completed

Keywords

Prospective Studies Sarcoma, Kaposi Herpesvirus 4, Human Acquired Immunodeficiency Syndrome Cohort Studies Risk Factors Lymphoma, Aids Related Antibodies, Viral Lymphoproliferative Disorders Viral Load Herpesvirus, Kaposi Sarcoma Associated Translocation (Genetics)

ClinConnect Summary

AIDS-associated malignancy represents a model system for investigations of carcinogenesis. There are few human conditions in which cancer rates are of the magnitude they are in HIV infection. While studies have investigated pre-cancer markers in HIV-infected patients, they have not correlated these markers with tumor samples. This study contributes to understanding oncogenesis of HIV-associated malignancies by establishing a collection of tumors linked with pre-cancer sera and lymphocyte specimens, as well as prospective questionnaire data.

At study entry, patients receive a comprehensive ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • You may be eligible for this trial if you:
  • Are HIV-positive.
  • Have a CD4+ cell count of 200 cells/mm3 or below.
  • Are 18 years of age or older.
  • Exclusion Criteria
  • You will not be eligible for this trial if you:
  • Are not available for follow-up for at least 3 years.

Trial Officials

David A. Wohl

Study Chair

Univ of North Carolina

Ann C. Collier

Study Chair

Univ of Washington

William G. Powderly

Study Chair

Charles S. Rabkin

Principal Investigator

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Indianapolis, Indiana, United States

Columbus, Ohio, United States

San Francisco, California, United States

Seattle, Washington, United States

New York, New York, United States

Rochester, New York, United States

Chapel Hill, North Carolina, United States

Durham, North Carolina, United States

Cleveland, Ohio, United States

Stanford, California, United States

Stanford, California, United States

Honolulu, Hawaii, United States

Baltimore, Maryland, United States

Buffalo, New York, United States

Cincinnati, Ohio, United States

Cleveland, Ohio, United States

New Orleans, Louisiana, United States

New Orleans, Louisiana, United States

New York, New York, United States

Boston, Massachusetts, United States

Menlo Park, California, United States

San Rafael, California, United States

Rochester, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials